Are you or someone you know about to start taking Invega Sustenna? It's important to understand the dosage and how it works. This comprehensive guide offers everything patients and caregivers need to know about Invega Sustenna dosage, from understanding what it treats, the different dosages available, when it should be taken, and much more.
Invega Sustenna is an antipsychotic medication that is used to treat schizophrenia and bipolar disorder. It is a long-acting injection that is given once every four weeks.
Invega Sustenna is a long-acting injectable antipsychotic medication used to treat schizophrenia and bipolar disorder. It is available in two strengths, 150 mg and 234 mg. The usual dose for treating schizophrenia is 234 mg once monthly. The usual dose for treating bipolar disorder is 150 mg once monthly. Invega Sustenna should be injected into the buttocks (upper outer quadrant) or upper arm (deltoid muscle). The injection site should be rotated between injections to avoid skin reactions. Invega Sustenna must be refrigerated at all times, but can be kept at room temperature for up to 14 days.
Invega Sustenna is an atypical antipsychotic medication that is used to treat schizophrenia and bipolar disorder. It is available in three different dosage strengths: 37.5 mg, 75 mg, and 150 mg. The different dosage strengths are designed to be taken at different intervals, depending on the severity of the condition being treated.
The 37.5 mg dosage strength is intended for patients who are starting treatment for the first time, or for those who have not responded well to other antipsychotic medications. It is typically taken once daily, either in the morning or evening.
The 75 mg dosage strength is typically reserved for patients who have been taking lower doses of Invega Sustenna and need to increase their dose in order to achieve optimal results. It is also sometimes used as an initial dose for patients who are considered to be at a high risk for relapse. This dose is taken once daily, either in the morning or evening.
The 150 mg dosage strength is typically only prescribed to patients who have not responded well to lower doses of Invega Sustenna. It is taken once daily, either in the morning or evening.
Invega Sustenna is a long-acting injectable antipsychotic medication used to treat adults with schizophrenia. The recommended dose of Invega Sustenna is 234 mg given once monthly as an intramuscular injection. The most common side effects of Invega Sustenna include akathisia (restlessness), weight gain, and insomnia. Akathisia may be treated with medications such as propranolol or benzodiazepines. Weight gain may be treated with lifestyle changes such as diet and exercise, and medications such as metformin or topiramate. Insomnia may be treated with over-the-counter sleep aids or behavioral changes such as avoiding caffeine before bedtime.
We hope this guide has provided you with a comprehensive understanding of Invega Sustenna dosage. With knowledge and insight into the medication's various strengths, administration methods, and side effects, patients can feel more comfortable when selecting an appropriate dose to best meet their health needs. It is important for both patients and caregivers alike to take all necessary precautions with Invega Sustenna in order to avoid any unwanted complications or adverse reactions from its use.
1.
Radioactive ion beams successfully treat animal tumors in study
2.
A computer-aided diagnostic system for improved detection of breast cancer.
3.
Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.
4.
Study reveals that older women frequently receive an incorrect breast cancer diagnosis.
5.
Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer
1.
The Impact of Microadenoma on Hormonal Health
2.
Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy
3.
ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection
4.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
5.
Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
2.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
3.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation